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a  b  s  t  r  a  c  t
Background: The timing of most recurrences after neonatal urinary tract infection is during
the ﬁrst year of life, with peak incidence 2–6 months after the initial infection. Information
on  the microbiologic characteristics of recurrent urinary tract infection episodes in relation
to  the microbiology of the initial episodes is limited.
Objectives: To analyze the epidemiologic/microbiological characteristics of 1st and recurrent
urinary tract infection in infants <2 months of age.
Methods: A retrospective study including all infants <2 months of age with urinary tract
infection admitted during 2005–2009 and followed till the age of 1 year.
Results: 151 neonates were enrolled (2.7% of all 5617 febrile infants <2 months of age
admitted). The overall incidence of urinary tract infection occurring during the ﬁrst 2
months of life was 151/73,480 (0.2%) live births during 2005–2009 in southern Israel
(2.1  cases/1000 live births). One pathogen was isolated in 133 (88.1%); Escherichia coli,
Klebsiella spp., Enterococcus spp., Morganella morganii, Proteus spp., and Enterobacter spp.
represented the most common pathogens (57.9%, 12.2%, 7.9%, 6.7%, 6.1%, and 5%, respec-tively). Trimethoprim/sulfamethoxazole, ampicillin, and cefuroxime-axetil were the most
commonly recommended prophylactic antibiotics (45%, 13.2%, and 8%, respectively).
nt urinary tract infection episodes were recorded in 20 (13.2%) patients;Twenty-three recurre6/23 (26%) were diagnosed within one month following 1st episode. E. coli was the most fre-
quent  recurrent urinary tract infection pathogen (12/23, 52.2%). No differences were recorded
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in E. coli distribution between ﬁrst urinary tract infection vs. recurrent urinary tract infec-
tion.  Seventeen (74%) recurrent urinary tract infection episodes were caused by pathogens
different (phenotypically) from those isolated in 1st episode. Recurrent urinary tract infec-
tion occurred in 25.0%, 8.3%, and 0 patients recommended trimethoprim/sulfamethoxazole,
cefuroxime-axetil, or amoxicillin prophylaxis, respectively.
Conclusions: (1) The study determined the incidence of urinary tract infection in febrile
infants <2 months of age in Southern Israel; (2) E. coli was responsible for the majority
of  ﬁrst and recurrent urinary tract infection; (3) recurrent urinary tract infection was caused
mostly by pathogens different than the pathogens isolated at initial episode.
©  2015 Elsevier Editora Ltda. All rights reserved.Introduction
The incidence of urinary tract infections (UTI) is 3–4.6% in
neonates, 0.7–5.9% in infants up to 1 year of age, 1–3% at the
age of 1–5 years and 0.71–2.3% at school age.1,2 Approximately
7–8% of girls and 2% of boys will develop an UTI during the ﬁrst
8 years of life.3 The most common pathogen is Escherichia coli,
causing up to 70–90% of all UTIs.4,5
Diagnosis of UTI is of major importance, particularly in
young ages, because the infection may represent, potentially,
the ﬁrst sign of a congenital defect of the urinary tract. Early
diagnosis and treatment are considered to prevent compli-
cations such as renal scarring, deteriorating renal function,
and hypertension, especially in young infants and children <5
years of age.6 The most common abnormality diagnosed by
imaging investigation is vesico-uretheral reﬂux (VUR).6–9 The
rate of VUR in children <1 year of age is between 18–35%.6,8,9
It is known today that severe VUR may be associated with
development of renal scars by up to 4–6 times more  than a
low grade VUR and 8–10 times more  likely than in patients
without VUR.6,8,9
The timing of most UTI recurrences after neonatal UTI is
during the ﬁrst year of life, with peak incidence 2–6 months
post infection.10 In general, UTI recurrence occurs in 30–40%
of the children with UTI and around 60% of them will have the
recurrence during the ﬁrst two years of life. In a retrospective
study completed between 1978 and 1984 and including 262
children <1 year of age followed for three years after the ﬁrst
episode, 35% boys and 32% girls developed recurrent UTI and
the recurrent UTI incidence was higher in children with higher
(III–V) degrees of reﬂux.11
Information on the microbiologic characteristics of the
recurrent UTI episodes in relation to the microbiology of the
initial episodes is limited. The objectives of our study are to
describe and characterize the 1st UTI episode in infants <2
months of age admitted at our center during 2005–2009, to
determine the incidence of UTI in this population in South-
ern Israel, to establish the rates of recurrent UTI episodes
until the age of 1 year and the microbiologic characteristics
of these episodes, and to discuss the appropriate antibiotic
treatment policies for the treatment and prophylaxis of UTI in
infants.Patients  and  methods
This was a retrospective study performed during 2005–2009
and including all the infants <2 months of age admitted to the
pediatric departments of the Soroka University Medical Center
with the diagnosis of UTI proven by urine culture (obtained by
supra-pubic aspiration or bladder catheterization). Our hospi-
tal is the only primary and tertiary medical center in Southern
Israel and takes care of a population of approximately 1 million
patients, out of them around 250,000 children.3
Infants <2 months of age, following the hospitaliza-
tion with UTI, were discharged with the recommendation
for antibiotic prophylaxis and for imaging investigations
of the urinary tract during the period of two months fol-
lowing the original UTI episode, according to the available
recommendations.6,8 The medical records of the admitted
infants, laboratory ﬁndings from the bacteriological labora-
tory and imaging data from the radiology department and
the nuclear medicine institute, were searched. Age, sex and
ethnicity of the infants with UTI were documented. All urine
cultures were obtained (at the initial and also the recur-
rent UTI episode) by catheterization or suprapubic aspiration.
The recovered urine cultures pathogens were considered true
uropathogens according to treatment physicians and addi-
tional recommendations by the pediatric infectious disease
unit of the hospital. Pseudomonas aeruginosa,  Staphylococ-
cus aureus,  and Candida albicans were not considered true
uropathogens in single pathogen or mixed pathogens-UTI
cases without an additional renal anatomic abnormality.
A comparative analysis of the microbiological factors
responsible for the ﬁrst and for the recurrent UTI  episodes was
performed. The antibiotic coverage and duration of treatment
of UTI were documented. The timing of the UTI recurrence
was analyzed in relation to the initial UTI episode. Anatomical
abnormalities diagnosed during the ﬁrst episode of UTI were
documented as well as all imaging ﬁnding completed during
the follow-up period. When VUR diagnosis was present, its
severity degree was reported.
The antibiotic prophylaxis policy was not well deﬁned at
the pediatric department during the study period, leaving at
the physicians’ decision the speciﬁc antibiotic to be adminis-
tered. However, the local guidelines recommended antibiotic
















































Table 1 – Pathogen distribution: 151 episodes of ﬁrst UTI
occurring in 151 neonates <2 months of age.
Pathogens n (%)
(1) Pathogen 133 (88.1)
Escherichia coli 85 (56.3)
Klebsiella spp. 16 (10.6)
Enterococcus spp. 8 (5.2)
Morganella morganii 8 (5.2)
Proteus spp. 7 (4.5)
Enterobacter spp. 6 (3.9)
Citrobacter spp. 2  (1.3)
Serratia marcescens 1  (0.6)
(2) Pathogens (mixed infection) 18  (11.9)
Escherichia coli + Enterococcus spp. 3 (1.9)
Escherichia coli + Klebsiella spp. 2  (1.3)
Escherichia coli + Proteus spp. 2  (1.3)
Escherichia coli + type b Haemophilus inﬂuenzae 1 (0.6)
Escherichia coli + Morganella morganii 1 (0.6)
Escherichia coli + Acinetobacter spp. 1 (0.6)
Klebsiella spp. + Enterococcus spp. 1 (0.6)
Klebsiella spp. + Pseudomonas spp. 1 (0.6)
Morganella morganii + Enterococcus spp. 1 (0.6)
Morganella morganii + Klebsiella spp. 1 (0.6)
Enterobacter spp. + Enterococcus spp. 1 (0.6)
Enterobacter spp. + Proteus spp. 1 (0.6)
Proteus spp. + Enterococcus spp. 1 (0.6)b r a z j i n f e c t d i
rophylaxis for all infants <2 months of age with ﬁrst UTI
pisodes until the completion of imaging studies.
The recommended imaging studies during the study period
ncluded the completion of an ultrasound (US) examination
uring hospitalization or after hospitalization in all cases of
nfants <2 months of age with UTI and performance of a
oiding cystourethrogram (VCUG) after 6–8 weeks following
he discharge from the hospital. Additional investigations,
ike Technetium-Dimercaptosuccinic (DMSA) scan, in speciﬁc
ases, were performed according to nephrologist’s recommen-
ations.
The study was approved by the ethics committee of the
ospital.
tatistical  analysis
ata were recorded using the Access Microsoft Ofﬁce software.
tatistical analysis was performed using the SPSS 16.0 soft-
are. Contingency table analysis for comparing rates between
nmatched samples was performed using the Chi-square
r Fisher’s exact test, as appropriate. Student’s independent
amples t-test or ANOVA were used to compare continuous
ariables.
esults
verall, 151 infants <2 month of age diagnosed with the 1st UTI
pisode in life, were enrolled. These infants represented 2.7%
f all 5617 infants <2 months of age admitted at the pediatric
epartments during the study years (22/1129 [1.9%], 34/1205
2.8%], 45/1302 [3.4%], 24/1217 [2.0%], and 26/1029 [2.5%] during
005, 2006, 2007, 2008, and 2009, respectively).
The overall incidence of UTI occurring during the ﬁrst
wo months of life was 151/73,480 (0.2%) live births during
005–2009 in the Negev area of Southern Israel, representing
n incidence of 2.1 cases/1000 live births. The respective num-
ers for each year of the study were: 1.5, 2.4, 3.1, 1.6, and
.7/1000 live births during 2005, 2006, 2007, 2008, and 2009
espectively.
The mean ± standard deviation age (in days) at UTI diag-
osis was 42.26 ± 31.25 days for the whole study population;
o differences were recorded in the mean age at ﬁrst UTI
iagnosis between male and female neonates (38.24 ± 15.8 vs.
2.26 ± 31.25, p = 0.06). There were 85 (56.3%) male patients (all
ircumcised) and 102 (67.5%) patients of Moslem Bedouin eth-
icity.
One hundred and twenty (79.5%) young infants with UTI
id not suffer from any previous pathologic conditions. The
emaining 31 (21.5%) were diagnosed with various anomalies,
f them 9 (5.9%) with renal anomalies (6 with hydronephrosis).
Concomitant pathologies were diagnosed at the time of
TI diagnosis in 25 (16.6%) patients with UTI; pneumonia and
ronchiolitis were diagnosed concomitantly in 8 (5.3%) cases
ach and bacterial meningitis in 5 (3.3%).icrobiology
ne pathogen was isolated in 133 (88.1%) UTI episodes.
scherichia coli, Klebsiella spp., Enterococcus spp., MorganellaEnterococcus spp. + Staphylococcus aureus 1(0.6)
morganii, Proteus spp., and Enterobacter spp. were the most fre-
quently isolated pathogens (53.3%, 10.6%, 5.2%, 5.2%, 4.5%, and
3.9% of all episodes, respectively) – Table 1. Mixed infection
caused by two organisms considered as true UTI pathogens
was recorded in 18 (11.9%) episodes, with E. coli isolated in
6/18 (33.3%) episodes. In the two patients with mixed UTI
with recovery of P. aeruginosa and S. aureus (together with Kleb-
siella spp. and Enterococcus spp., respectively), both isolates
were considered as true uropathogens due to the concomi-
tant presence of renal tract anatomic anomalies (moderate
hydronephrosis and VUR degree IV, respectively).
Overall, there were 169 uropathogens, of them 95 (57.9%) E.
coli isolates. Klebsiella spp., Enterococcus spp., M.  morganii, Pro-
teus spp., and Enterobacter spp. represented the most common
UTI pathogens isolated (in decreasing frequency) following
E. coli (12.2%, 7.9%, 6.7%, 6.1%, and 5% of all pathogens, respec-
tively).
No statistical differences were recorded between E. coli-UTI
cases recorded in male vs. female patients (68.2% vs. 56%,
p = 0.5). Signiﬁcantly more  E. coli-UTI cases were recorded in
Bedouin patients compared with Jewish patients (70.6% vs.
46.9%, p = 0.005).
Antibiotic  prophylaxis  following  the  ﬁrst  UTI  episodes
Trimethoprim/sulfamethoxazole (TMP/SMX) was the most
common prophylactic antibiotic recommended (68, 45% of
all enrolled patients) in the study patients following the ﬁrst
UTI episodes. Amoxicillin and cefuroxime-axetil were the
next most common prophylactic antibiotic recommended
(20 [13.2%] and 12 [8%] of all enrolled patients). Forty-ﬁve
(29.8%) of the patients enrolled in the study did not receive
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Table 2 – Epidemiologic, microbiologic, and therapeutic characteristics: 20 patients (23 episodes) with UTI recurrence.










1 F 12 E. coli E. coli TMP/SMX
2 M 1 Proteus spp. C. albicans TMP/SMX
3 F 2 Proteus spp. P. aeruginosa TMP/SMX
4 F 3 E. coli Citrobacter spp. TMP/SMX
5 M 2 Enterobacter spp. + Enterococcus spp. E. coli TMP/SMX
6 F 2 E. coli Enterobacter spp. NA
7 M 2 E. coli Klebsiella spp. NA
8 M 3 E. coli E. coli TMP/SMX
9 F 3 E. coli E. coli Cefuroxime-axetil
10 M 6 E. coli E. coli TMP/SMX
11 F 4 M. morganii E. coli TMP/SMX
12 M 7 E. coli E. coli TMP/SMX
13 M 6 E. coli E. coli TMP/SMX
14 F 11 Proteus spp. E. coli NA
15 M 11 Hydronephrosis Enterobacter spp. Enterococcus spp. TMP/SMX
16 M 10 Hydronephrosis Enterobacter spp. Enterobacter spp. TMP/SMX
17 M 4 E. coli E. coli NA
18.1
M
7 Klebsiella spp. Proteus spp. TMP/SMX







Klebsiella spp. S. aureus TMP/SMX
19.2 7 Klebsiella spp. C. albicans TMP/SMX
19.3 10 Klebsiella spp. E. coli TMP/SMX
20 M 12 Klebsiella spp. Klebsiella spp. NA
VJ, urTMP/SMX, trimethoprim/sulfamethoxazole; NA, not administered; U
any recommendation for antibiotic prophylaxis following the
initial UTI episode.
Imaging  studies
US was performed in 83 (54.9%) patients; 68 (81.9%) of these
examinations were reported as normal. The abnormal ﬁnd-
ings diagnosed in 15 (18.1%) patients included: mild to severe
hydronephrosis in all cases, one megaureter and one case sus-
pected of nephrolithiasis. VCUG was performed in 66 (43.7%)
and was diagnosed as normal in 52 (78.8%); VUR of degrees
IV–V was found in three patients.
Recurrent  UTI  (Table  2)
Recurrent UTI episodes were recorded in 20/151 (13.2%)
patients. One patient developed two UTI recurrences during
the ﬁrst year of life and one patient developed three UTI recur-
rences within the ﬁrst year of life. Recurrent UTI was recorded
in 13 males and seven female patients; 6/23 (26%) recurrent
UTI episode were diagnosed within one month following the
discharge after the ﬁrst UTI episode. Three of the patients with
recurrent UTI had a previously diagnosed renal abnormality
(all three with hydronephrosis, one of them with urethero-
vesicular obstruction)
Five of the patients with recurrent UTI did not receive
any antibiotic prophylaxis following the ﬁrst UTI episode.
There were 23 uropathogens; no mixed pathogens recurrent
UTI episodes were recorded. E. coli was the most frequent
UTI pathogen recovered in recurrent UTI (12/23, 52.2% of all
recurrent UTI episodes). No differences were recorded in the
representation of E. coli among all the pathogens isolated in theethero-vesicular junction.
ﬁrst UTI episodes compared with the recurrent UTI episodes
(95/151, 62.9% vs. 12/23, 52.2%, p = 0.30).
Seventeen (74%) of the 23 episodes of recurrent UTI were
caused by pathogens different (phenotypically) from the
pathogen isolated at the ﬁrst UTI episode. In two of these
episodes, the initial and recurrent UTI pathogen was E. coli
with a different antibiotic susceptibility proﬁle. Six (26%) of the
23 episodes of recurrent UTI were caused by the same (phe-
notypically) pathogens as those causing the ﬁrst UTI episode:
four E. coli, one Klebsiella spp. and one Enterobacter spp.
Recurrent UTI episodes occurred in 17/68 (25.0%), 1/12
(8.3%), and 0/20 of patients receiving initial prophylaxis with
TMP/SMX, cefuroxime-axetil, or amoxicillin, respectively.
Antibiotic  susceptibilities  of  uropathogens  isolated  at  the
initial and  recurrent  UTI  episode  (Table  3)
At the initial UTI episode, the antibiotic resistance of E. coli iso-
lates to the most commonly used oral antibiotics was 57.9%,
13.5%, 9.9%, and 5.4% for ampicillin, amoxicillin/clavulanic
acid, TMP/SMX, and cefuroxime-axetil. The respective num-
bers for the two most commonly used IM/IV antibiotic drugs
were 3.9% and 2.1% for ceftriaxone and gentamicin. The
antibiotic resistance of Klebsiella spp. isolates to the most com-
monly used oral antibiotics was 90.0%, 21.4%, 14.3%, and 6.3%
for ampicillin, amoxicillin/clavulanic acid, cefuroxime-axetil,
and TMP/SMX. The respective numbers for the two most com-
monly used IM/IV antibiotic drugs were 6.3% and 4.8% for
ceftriaxone and gentamicin. All 11 M. morganii isolates were



















































n  = 11
II
n  = 0
I




n  = 8
II
n  = 2
I
n  = 14
II
n  = 1
Ampicillin 55/95 (57.9) 7/12 (58.3) 18/20 (90) 2/2 (100) 11/11 (100) 7/11 (63.6) 2/2 (100) 7/8 (87.5) 2/2 (100) 0/13 1/1 (100)
TMP/SMX 7/71 (9.9) 0/10 1/16 (6.3) 0/2 2/8 (25) 0/5 1/1 (100) 0/6 – 2/10 (20) –
Cefuroxime 5/92 (5.4) 0/10 3/21 (14.3) 1/2 (50) 1/10 (10) 0/11 0/1 1/7 (14.3) 2/2 (100) 3/10 (30) –
Ceftriaxone 3/77 (3.9) 2/12 (100) 1/16 (6.3) 0/1 2/9 (22.2) 1/11 (9.1) – 0/7 2/2 (100) 3/8 (37.5) –
Gentamicin 2/94 (2.1) 0/12 1/21 (4.8) – 3/11 (27.3) 0/11 0/1 0/8 0/2 2/13 (15.4) 0/1
Amoxicillin/clavulanic acid 5/37 (13.5) 4/5 (80) 3/14 (21.4) – 1/4 (25) 4/9 (44.4) – 1/1 (100) 1/1 (100) 3/7 (42.9) –
Ciproﬂoxacin 3/29 (10.3) 0/1 2/5 (40) – 1/3 (33.3) 2/5 (40) – 0/1 – 6/7 (85.7) –
∗ Antibiotic susceptibilities for some antibiotic drugs not determined for all pathogens.
∗∗ I, initial UTI episode; II, recurrent UTI episode.
TMP/SMX, trimethoprim/sulfamethoxazole.
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The antibiotic resistance of the 12 E. coli isolates recov-
ered in R-UTI patients was 58.3%, 0%, and 0% for ampicillin,
TMP/SMX, and cefuroxime-axetil, respectively. Four of the
ﬁve E. coli isolates examined showed resistance to amoxi-
cillin/clavulanic acid. The respective numbers for the two
most commonly used IM/IV antibiotic drugs were 16.6% and 0
for ceftriaxone and gentamicin.
Discussion
The most recently published information on the diagnosis
and management of an initial UTI episode in febrile infants
and young children are included in the last (2011) technical
report of the subcommittee of UTI of the American Academy of
Pediatrics.7 A meta-analysis was performed on a ﬁnal amount
of 159 relevant publications and revealed a consistent UTI
prevalence of 5% among infants and young children 2–24
months of age with fever without obvious source. Evidence
was found that delay in the institution of appropriate treat-
ment of pyelonephritis increases the risk of renal damage. A
prevalence of VUR of 18–35% among infants/young children
with UTI was reported. The report emphasized that normal
prenatal US ﬁndings may not be sufﬁcient to obviate the
need for additional studies if a UTI occurs in infancy and
that the accumulated evidence was not supporting antimi-
crobial prophylaxis to prevent UTI when VUR is found through
VCUG. Finally, performance of VCUG after the ﬁrst UTI for chil-
dren between 2 and 24 months of age was not recommended
anymore.7 The following (2011) guidelines of the American
Academy of Pediatrics did not support the use of antimicro-
bial prophylaxis to prevent febrile recurrent UTI in infants
without grade I–IV VUR.9 VCUG was not recommended any-
more  routinely after the ﬁrst UTI, but is still indicated if renal
and bladder ultrasonography reveals hydronephrosis, scar-
ing, or other ﬁnding suggestive of either high grade VUR or
obstructive uropathy and in other atypical or complex clinical
circumstances. The performance of VCUG, however, is recom-
mended in the presence of a recurrence of febrile UTI.9
Few data exist in the literature regarding UTIs occurring in
infants <2 months of age. The major purpose of our retrospec-
tive study was to analyze the epidemiological, microbiological,
imaging, and therapeutical aspects of the ﬁrst episodes of UTI
in infants <2 months of age and to follow these infants until
the age of one year, in order to track the occurrence of recur-
rent UTI episodes and to study the appropriateness of current
imaging and antibiotic therapeutic guidelines. The major ﬁnd-
ings of this study were: (1) the UTI incidence was 2.1 cases/1000
live births among infants <2 months of age in Southern Israel;
(2) E. coli was responsible for the majority of ﬁrst and also
recurrent UTI episodes; (3) no differences were recorded in the
percentages of E. coli among the pathogens isolated at the ﬁrst
and the recurrent UTI episodes; (4) the adherence to diagnostic
imaging guidelines for infants <2 months of age with ﬁrst UTI
episodes was partial; (5) recurrent UTI episodes were recorded
in relatively few (13.2%) patients and were caused mostly by
pathogens phenotypically different than the pathogen iso-
lated at the initial episode; (6) while high rates of resistance
to ampicillin were recorded among the E. coli and Klebsiella
spp. isolates in the ﬁrst UTI episode and among E. coli isolates 0 1 6;2  0(1):19–25
at UTI recurrence, the resistance rate of these pathogens to
TMP/SMX and cefuroxime-axetil were low.
We calculated in our study an UTI incidence of 2.1/1000
live births among infants aged 0–2 months living in the Negev
area of Southern Israel and a prevalence of 2.7% cases of ﬁrst
UTI episode in life among febrile infants <2 months admit-
ted at the pediatric departments of our hospital during the
study years. The prevalence rates are lower than the ﬁgures
published in the medical literature (reporting a rate of around
5%).1,4,5,8 The incidence rate reported in our study should be
considered reliable, because all our ﬁndings are reported in
this study as population-based, taking into consideration that
the Soroka University Medical Center is the only medical cen-
ter treating infants and children in the Negev area of southern
Israel.
E. coli was responsible for the majority of cases of ﬁrst UTI.
Our data are similar to data previously published in the lit-
erature showing a representation of E. coli among ﬁrst UTI
episodes of 60–89%.8,12,13 The current guidelines for the treat-
ment of neonatal UTI take into consideration these ﬁnding
but may often be inappropriate for hospitalized infants with
non-E. coli UTI, caused in general by pathogens resistant to
antibiotics and therefore more  difﬁcult to treat.13 The E. coli
isolates recovered from our patients at the ﬁrst UTI episode,
although resistant, in most patients, to ampicillin and also
in a considerable number of cases to amoxicillin/clavulanic
acid, showed a favorable antibiotic susceptibility proﬁle vs.
TMP/SMX, cefuroxime, ceftriaxone, and gentamicin. Further-
more,  the resistance rates of Klebsiella spp. to TMP/SMX were
also very low. Therefore, and not in accordance with the pub-
lished literature, TMP/SMX may represent, at least in older
children, an acceptable ﬁrst line empiric antibiotic in the treat-
ment of UTI in young infants.
The R-UTI rates recorded in our study reached 13.2% fol-
lowing an initial UTI episode occurring during the ﬁrst two
months of life. Most prior studies have shown much higher
recurrence rate (20–48%) of UTI 6–12 months after an initial UTI
episode.7,9,14 Interestingly, only a few of the patients develop-
ing R-UTI episodes in our study had a previously diagnosed
renal pathology. The inﬂuence of the antibiotic prophylac-
tic treatment administered after the ﬁrst UTI episode could
not be clearly determined in our study. However, 25% of the
patients receiving prophylaxis with TMP/SMX developed R-
UTI episodes (despite low resistance to this antibiotic drug)
while no cases of recurrent UTI were diagnosed in patients
receiving amoxicillin prophylaxis (despite an unfavorable sus-
ceptibility proﬁle of the most frequently isolates pathogens
recovered in this study). The effectiveness of long-term pro-
phylactic antibiotic treatment is yet unclear.6,7,8,9 Williams
et al.15 showed that long-term antibiotic prophylaxis is effec-
tive in preventing UTI recurrences, but this effect was not
sustained after the interruption of the antibiotic treatment.
Shah et al. determined that prophylactic antibiotic is recom-
mended for children <8 years of age with VUR and frequent
symptomatic recurrences of UTI (≥2 UTI episodes over a 6-
month period) and in young children <18 months of age
with acute pyelonephritis without any diagnosed reﬂux using
99mTc-DMSA scan.16 On the other hand, Garin et al. deter-
mined that the presence of VUR of mild or moderate degree
does not increase the risk for R-UTI, pyelonephritis, or kidney
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carring and there is no reason for prophylactic antibiotic.17
onway et al.10 reported rates of 0.007 episodes per person-
ear of primary UTI up to the age of one year and 0.12 episodes
er person-year of recurrent UTI. The authors found that the
isk factors for recurrence of UTI included white race, age of
–5 years, and a VUR of degrees 4–5. Prophylactic antibiotic
reatment was not associated with a decrease in the risk of UTI
ecurrence, but was a risk factor for development of antimicro-
ial resistance among children with recurrent UTI.10 In 2014,
n a two-year, multisite, randomized, placebo-controlled trial
nvolving 607 children with VUR (80.4% with grade II or III VUR)
iagnosed after a ﬁrst or second febrile or symptomatic uri-
ary tract infection, antimicrobial prophylaxis with TMP/SMX
as associated with a substantially reduced risk of recurrence
50%) but not of renal scarring.18
We  could establish in this study that the overall etiology
f the recurrent UTI episodes was similar to that of the ini-
ial UTI episode in terms of E. coli and non-E. coli organisms
epresentation and also, importantly, that the majority (64%)
f the recurrent UTI episodes were caused by pathogens dif-
erent than those isolated at the ﬁrst UTI episode. Our last
ndings, based on similarity between the antimicrobial pro-
les of the isolates, were not deﬁnitively conﬁrmed by genetic
ests demonstrating unequivocally this similarity, and this is
ne of the limitations of our study.
The imaging guidelines in use at the pediatric division of
ur hospital during the study period recommended the per-
ormance of US examination during hospitalization or shortly
fter hospitalization in all cases of UTI in young infants, a
CUG examination after 6–8 weeks following the discharge
rom the hospital. These guidelines were implemented only
artially in the enrolled patients.
In conclusion, our study showed that E. coli was respon-
ible for the majority of ﬁrst UTI in neonates and also in
he recurrent UTI episodes of these patients. We  could not
nd any differences in the percentages of E. coli and non-
. coli organisms between the ﬁrst and the recurrent UTI
pisodes. Recurrent UTI episodes were recorded in relatively
ew patients and were caused mostly by pathogens pheno-
ypically different than the pathogen isolated at the initial
pisode.
onﬂicts  of  interest
he authors declare no conﬂicts of interest.
 e  f  e  r  e  n  c  e  s1. Hoberman A, Chao HP, Keller DM, Hickey R, Davis HW, Ellis D.
Prevalence of urinary tract infection in febrile infants. J
Pediatr. 1993;123:17–23.
1 1 6;2  0(1):19–25 25
2. Miron D, Shatzberg G, Landau D, Halevy R. Treatment of
community-acquired urinary tract infections. Israel J Pediatr.
2001;38:7–15.
3. Israeli Central Bureau of Statistics, Statistical Abstracts of
Israel, 2005-2009, Data on Beer-Sheva sub-district population.
4.  Ismaili K, Lolin K, Damry N, Alexander M, Lepage P, Hall M.
Febrile urinary tract infections in 0- to 3-month-old infants: a
prospective follow-up study. J Pediatr. 2011;158:91–4.
5. Roberts KB, Charney E, Sweren RJ, Ahonkhai VI, Bergman DA,
Coulter MP, et al. Urinary tract infection in infants with
unexplained fever: a collaborative study. J Pediatr.
1983;103:864–7.
6. American Academy of Pediatrics. Committee on Quality
Improvement. Subcommittee on Urinary Tract Infection.
Practice parameter: the diagnosis, treatment, and evaluation
of  the initial urinary tract infection in febrile infants and
young children. Pediatrics. 1999;103:843–52.
7. Finnell SME, Carroll AE, Downs. SM and the Subcommittee on
Urinary Tract Infection. Technical report- diagnosis and
management of an initial UTI in febrile infants and young
children. American Academy of Pediatrics. Pediatrics.
2011;128:e749–70.
8. Roberts KB. Urinary tract infection treatment and evaluation.
Update. Pediatr Infect Dis J. 2004;23:1163–4.
9. Subcommittee on Urinary Tract Infection. Steering committee
on Quality Improvement and Management: Clinical Practice
Guideline for the Diagnosis and Management of the Initial
UTI  in Febrile Infants and Children 2 to 24 months. American
Academy of Pediatrics. Pediatrics. 2011;128:595–610.
0. Conway PH, Cnaan A, Zaoutis T, Henry BV, Grundmeier RW,
Keren. Recurrent urinary tract infections in children. Risk
factors and association with prophylactic antimicrobials.
JAMA. 2007;298:179–87.
1. Nuutinen M, Uhari M. Recurrence and follow-up after urinary
tract infection under the age of 1 year. Pediatr Nephrol.
2001;16:69–72.
2. Ismaili K, Wissing KM, Lolin K, Le PQ, Christophe C, Lepage P,
et  al. Characteristics of ﬁrst urinary tract infection with fever
in  children – a prospective clinical and imaging study. Pediatr
Infect Dis J. 2011;30:371–4.
3. Marcus N, Ashkenazi S, Yaari A, Samra Z, Livni G.
Non-Escherichia coli versus Escherichia coli community-acquired
urinary tract infection in children hospitalized in a tertiary
center-relative frequency, risk factors, antimicrobial
resistance and outcome. Pediatr Infect Dis J. 2005;24:581–5.
4. Wald ER. Vesicoureteral reﬂux: the role of antibiotic
prophylaxis. Pediatrics. 2006;117:919–22.
5. Williams G, Lee A, Craig J. Antibiotics for the prevention of
urinary tract infection in children: a systematic review of
randomized controlled trials. J Pediatrics. 2001;138:868–74.
6. Shah G, Upadhyay J. Controversies in the diagnosis and
management or urinary tract infections in children. Pediatr
Drugs. 2005;7:339–46.
7. Garin E, Olavarria F, Nieto VG, Valenciano B, Campos A, Young
L.  Clinical signiﬁcance of primary vesicoureteral reﬂux and
urinary antibiotic prophylaxis after acute pyelonephritis: a
multicenter, randomized, controlled study. Pediatrics.
2006;117:626–32.
8. The RIVUR Trial Investigators. Antimicrobial prophylaxis for
children with vesicoureteral reﬂux. N Engl J Med. 2014,
http://dx.doi.org/10.1056/NEJMoa1401811.
